321 related articles for article (PubMed ID: 29944867)
1. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
2. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
[TBL] [Abstract][Full Text] [Related]
4. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
6. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
[TBL] [Abstract][Full Text] [Related]
7. Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients.
Zhou F; Guo L
Hematology; 2022 Dec; 27(1):596-602. PubMed ID: 35617291
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
Nian F; Zhu J; Chang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y
Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
11. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
12. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Che F; Ye X; Wang Y; Ma S; Wang X
Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
[TBL] [Abstract][Full Text] [Related]
13. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
Ma NY; Li Q; Li XL; Zeng YJ; Huang DZ; Duan YS; Xia J; Liu BD; Rao LY; Rao J; Zhang X
Curr Med Sci; 2023 Aug; 43(4):679-688. PubMed ID: 37326888
[TBL] [Abstract][Full Text] [Related]
14. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
15. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
16. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
17. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
19. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]